First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options

Area of Science:

• Oncology
• Medical Research
• Pharmacology

Background:

• Historically, front-line treatment for metastatic clear-cell renal cell carcinoma (mRCC) was dichotomized into either targeted therapy (e.g., VEGF inhibitors) or immunotherapy (e.g., nivolumab/ipilimumab).
• This approach was primarily for intermediate/poor International Metastatic RCC Database Consortium (IMDC)-risk disease patients.

Purpose of the Study:

• To provide a comprehensive overview of recent datasets and emerging treatment strategies for newly diagnosed mRCC.
• To facilitate informed treatment decisions by contextualizing new therapeutic regimens.

Main Methods:

• Review of recent clinical trial data and regulatory approvals.
• Analysis of combined therapy regimens involving vascular endothelial growth factor (VEGF) inhibitors and checkpoint inhibitors.

Main Results:

• Recent approvals include combined regimens of VEGF inhibitors (e.g., axitinib) with checkpoint inhibitors (e.g., avelumab, pembrolizumab).
• These novel combinations represent a shift from previous monotherapy approaches in first-line mRCC treatment.

Conclusions:

• The landscape of first-line mRCC treatment has evolved with the introduction of combination therapies.
• These new regimens offer additional therapeutic options for patients with newly diagnosed mRCC, necessitating a re-evaluation of treatment strategies.